当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lenalidomide plus dexamethasone in multiple myeloma
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-11-23 , DOI: 10.1016/s1470-2045(17)30894-x Manjulika Das
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-11-23 , DOI: 10.1016/s1470-2045(17)30894-x Manjulika Das
In transplant-ineligible patients with newly diagnosed multiple myeloma, continuous treatment with lenalidomide plus dexamethasone improves survival outcomes, according to new research.
中文翻译:
来那度胺联合地塞米松治疗多发性骨髓瘤
根据新的研究,在不适合移植的新诊断的多发性骨髓瘤患者中,来那度胺联合地塞米松的连续治疗可改善生存率。
更新日期:2017-12-31
中文翻译:
来那度胺联合地塞米松治疗多发性骨髓瘤
根据新的研究,在不适合移植的新诊断的多发性骨髓瘤患者中,来那度胺联合地塞米松的连续治疗可改善生存率。